GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Annexon Inc.
Annexon is a biotech company specializing in the treatment of autoimmune and neurodegenerative diseases. Its stock price reflects the risks and hopes associated with its scientific platform. The chart is a history of ups and downs based on clinical trial data.
Share prices of companies in the market segment - Neuro
Annexon (ANNX) is a biopharmaceutical company developing a new class of drugs targeting C1q and the classical complement cascade for the treatment of autoimmune and neurodegenerative diseases. We classify the company as a Neuroscience company. The chart below shows the dynamics of this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
Annexon is a biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the complement system. Its scientific approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Annexon compares to it.
Change in the price of a company, segment, and market as a whole per day
ANNX - Daily change in the company's share price Annexon Inc.
The volatility of Annexon, a biopharmaceutical company, reflects the risks and hopes of treating neurodegenerative diseases. Change_co measures sensitivity to clinical trial results. This parameter is important for formulas on System.GURU.Markets that analyze high-risk biotech companies.
Daily change in the price of a set of shares in a market segment - Neuro
Annexon, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with ANNX, which focuses on treating autoimmune and neurodegenerative diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Annexon is a biopharmaceutical company specializing in drugs for the treatment of neurodegenerative diseases. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Annexon's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Annexon Inc.
For Annexon, Inc., the year-over-year trend is a story of developing drugs targeting the classical complement system for the treatment of neurodegenerative diseases. Its 12-month market cap depends entirely on clinical trial results. Success in this complex area could lead to the creation of a new class of drugs.
Annual dynamics of market capitalization of the market segment - Neuro
Annexon, Inc. is a clinical-stage biotech company developing drugs for the treatment of autoimmune and neurodegenerative diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Annexon is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Annexon Inc.
Annexon, a biopharmaceutical company, is driven by its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials of its drugs for neurodegenerative and autoimmune diseases, the success of which determines the potential of its scientific platform.
Monthly dynamics of market capitalization of the market segment - Neuro
Developing drugs to treat neuroinflammatory diseases is a complex and risky area of biotech. The dynamics of this sector, as seen in the chart, reflect its volatility and dependence on scientific data. In this context, companies like Annexon are pursuing new therapeutic approaches.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Annexon is a biotech company focused on treating autoimmune and neurodegenerative diseases. Its stock moves based on clinical trial results, completely disconnected from overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Annexon Inc.
Annexon, a biotech company focused on treating neurodegenerative and autoimmune diseases, operates at the forefront of science. Its weekly stock price is a direct response to clinical trial data, which can either confirm or refute its scientific approach, causing sharp fluctuations.
Weekly dynamics of market capitalization of the market segment - Neuro
Biotech companies working in immunology, like Annexon, are riding the wave of general news about scientific breakthroughs in this field. The chart below illustrates this general sentiment. It allows one to assess how promising the market perceives Annexon's technology compared to other companies in this field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Annexon is a biotech company focused on treating neurodegenerative and autoimmune diseases. Its shares are driven by news of clinical trials. The chart clearly demonstrates how their performance can be completely disconnected from overall market movements.
Market capitalization of the company, segment and market as a whole
ANNX - Market capitalization of the company Annexon Inc.
Annexon's market capitalization chart reflects investors' assessment of its scientific approach to treating neurodegenerative and autoimmune diseases. Its dynamics reflect the market's belief that blocking a specific immune system protein can halt nerve damage. Its price is a bet on the potential of this new therapeutic target.
ANNX - Share of the company's market capitalization Annexon Inc. within the market segment - Neuro
Annexon is a biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases by targeting the classical complement system. Its market capitalization in the neuroscience sector reflects the potential of this new approach. The company's size reflects its bet that its drugs will be effective in treating a broad range of diseases.
Market capitalization of the market segment - Neuro
This chart represents the combined weight of the entire neuroscience pharmaceutical sector. For Annexon, with its unique approach targeting the complement system, this line is a map of new scientific horizons. The rising chart shows how willing investors are to fund innovative approaches to treating brain diseases, where the company is seeking its breakthrough.
Market capitalization of all companies included in a broad market index - GURU.Markets
Annexon is a biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases. Its capitalization is a bet on a new approach to combating diseases in which the immune system attacks the body itself.
Book value capitalization of the company, segment and market as a whole
ANNX - Book value capitalization of the company Annexon Inc.
Annexon, Inc. is a biotechnology company focused on treating autoimmune and neurodegenerative diseases. Its book value is its financial capital for R&D, which consists of funds for clinical trials. How has this innovation budget changed? The chart below shows.
ANNX - Share of the company's book capitalization Annexon Inc. within the market segment - Neuro
Annexon, Inc. is a biotechnology company focused on the classical complement cascade. Its research requires a modern infrastructure, including a laboratory for developing and testing antibodies for the treatment of neurodegenerative diseases. The chart shows the company's share of the physical R&D infrastructure in this segment.
Market segment balance sheet capitalization - Neuro
Annexon, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Annexon's capital is not its manufacturing facilities, but its scientific platform for developing antibodies that block the C1q component for the treatment of neurodegenerative and autoimmune diseases. Its book value reflects its investment in R&D. The chart shows how this knowledge-intensive asset is valued within the biotech sector.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Annexon Inc.
Annexon's balance sheet is its R&D capital. Its entire market value is a premium for its scientific platform for treating neurodegenerative diseases. Its price is investors' bet that its approach will prove breakthrough.
Market to book capitalization ratio in a market segment - Neuro
Annexon is a biotech company developing drugs to treat neurodegenerative and autoimmune diseases. Its high valuation on this chart reflects investors' faith in its scientific approach targeting the classical complement pathway.
Market to book capitalization ratio for the market as a whole
Annexon is a biotech company working on treating neurodegenerative and autoimmune diseases. Its market value is based on the potential of its scientific platform. Like many biotech companies, its valuation is a bet on a future medical breakthrough, as the chart demonstrates.
Debts of the company, segment and market as a whole
ANNX - Company debts Annexon Inc.
Annexon, a biotech company focused on treating autoimmune and neurodegenerative diseases, uses capital to fund its clinical programs. This chart shows how the company is raising significant funds to test its scientific hypothesis targeting a new class of diseases, which requires large and risky investments.
Market segment debts - Neuro
Annexon is a clinical-stage biotech company developing drugs for the treatment of autoimmune and neurodegenerative diseases. Funding at this stage relies almost entirely on equity. This chart illustrates a typical industry-standard financial model with minimal or no leverage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Annexon Inc.
Annexon is a biopharmaceutical company focused on treating autoimmune and neurodegenerative diseases. This chart shows how it finances its expensive research. It's a measure of financial risk: the higher the debt, the greater the stake that its scientific approach will be correct and lead to the development of a sought-after drug.
Market segment debt to market segment book capitalization - Neuro
Annexon is a biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases. Its approach is based on blocking a specific protein in the immune system. The chart shows how the sector uses debt for R&D, which helps assess how Annexon funds its clinical trials.
Debt to book value of all companies in the market
#VALUE!
P/E of the company, segment and market as a whole
P/E - Annexon Inc.
Annexon is a clinical-stage biotech company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the complement system. This chart shows how the market values its scientific platform. This value is based on the potential of its targeted treatment approach.
P/E of the market segment - Neuro
Annexon develops drugs targeting the complement system. This chart shows the average valuation for the biotech sector. It serves as a backdrop for Annexon's valuation: investors look not at its profits, but at the potential of its scientific platform to treat a wide range of diseases.
P/E of the market as a whole
Annexon, Inc. is a biopharmaceutical company developing a new class of drugs to treat autoimmune and neurodegenerative diseases by inhibiting the complement system. This chart reflects investors' overall risk appetite. It helps understand whether ANNX's valuation is based on faith in its unique scientific approach or whether it moves in line with overall biotech sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Annexon Inc.
Annexon is a biotech company developing drugs to treat autoimmune and neurodegenerative diseases. Its future profitability depends on the success of its clinical trials. This chart shows market expectations regarding its scientific approach and the potential of its drug candidates.
%20P%2FE%20Annexon%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Annexon-Inc.&v=1772604423913 "Chart of the company's future (projected) P/E Annexon Inc.")
Future (projected) P/E of the market segment - Neuro
Annexon is a biotech pioneering the development of drugs targeting C1q, a protein that initiates the classical complement cascade, for the treatment of autoimmune and neurodegenerative diseases. The data here reflects the analysts' collective bet on the success of its unique scientific approach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772604423966 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Annexon is a biotech company developing drugs to treat autoimmune and neurodegenerative diseases. Their approach is based on inhibiting the complement cascade. This general sentiment chart shows how willing investors are to invest in innovative scientific platforms with broad potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772604424099 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Annexon Inc.
Annexon is a biotech company developing drugs targeting a component of the immune system believed to play a role in neurodegenerative diseases. This chart shows the financial impact of research and development. It reflects investments in a new approach to treating Alzheimer's and Huntington's diseases.
Profit of companies in the market segment - Neuro
Annexon is a biopharmaceutical company specializing in the treatment of autoimmune and neurodegenerative diseases by targeting the classical complement cascade. Currently in the clinical stage, it operates at the forefront of science. Its financial success depends on the confirmation of its scientific hypothesis in clinical trials.
Overall market profit
Annexon is a biotech company specializing in the treatment of autoimmune and neurodegenerative diseases. Its value depends on the success of its scientific platform. While there's no direct correlation with the economy, the overall state of the markets, reflected in this chart, determines the availability of venture capital, which is the only lifeline for such companies in the development stage.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Annexon Inc.
Annexon is a biotech company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the complement system. This chart shows analysts' speculative expectations. The forecast is entirely dependent on the success of their new approach in clinical trials.
%20profit%20of%20the%20company%20Annexon%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Annexon-Inc.&v=1772604424380 "Graph of future (projected) profit of the company Annexon Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Annexon is a biotech company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the complement component C1q. The profitability forecasts for this sector, shown in this chart, highlight the strong interest in immunology. This chart helps assess the potential of Annexon's platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772604424471 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Annexon is a biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases. Its value is based on the potential of its scientific developments. Financing such long-term and risky projects is facilitated by the market optimism that accompanies the positive outlook shown in this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772604424606 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Annexon Inc.
Annexon is a biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the complement system. It has no commercial revenue. This chart shows how investors view its scientific approach, which could become the basis for treating a wide range of diseases.
P/S market segment - Neuro
Annexon is a biopharmaceutical company developing drugs targeting the classical complement cascade for the treatment of autoimmune and neurodegenerative diseases. This metric reflects the average revenue estimate for the sector and helps understand the market premium for innovative approaches to treating complex diseases.
P/S of the market as a whole
Annexon is a biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the complement component C1q. This chart provides context for understanding how investors value companies with existing revenues compared to biotech companies targeting new biological targets.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Annexon Inc.
Annexon is a biotech company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the complement system. This chart reflects investors' high valuation of its potential future revenue. This valuation is a bet on the success of its unique scientific approach.
%20P%2FS%20Annexon%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Annexon-Inc.&v=1772604424881 "The graph of the company's future (projected) P/S Annexon Inc.")
Future (projected) P/S of the market segment - Neuro
Annexon is a biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the complement system. This chart compares market expectations for its future revenue with other neuroscience companies. The valuation reflects investor confidence in its scientific approach and clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772604424940 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Annexon is a clinical-stage biotech company developing drugs for the treatment of autoimmune and neurodegenerative diseases. Its value depends on the success of its scientific platform. This graph of overall market expectations for Annexon is merely a backdrop; its future is determined by the results of clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772604424950 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Annexon Inc.
This figure shows the revenue of Annexon, a biotech company focused on treating autoimmune and neurodegenerative diseases by targeting the complement component C1q. Being in the clinical stage, the company has no sales revenue. The chart confirms this, and its value is determined solely by the potential of its scientific platform.
Sales of companies in the market segment - Neuro
Annexon is a clinical-stage biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the complement system. This chart shows revenue in the neuroscience sector. It reflects scientific progress in understanding the role of the immune system in brain diseases, where Annexon's approach could form the basis for new therapies.
Overall market sales
Annexon, Inc. is a biotechnology company developing drugs to treat autoimmune and neurodegenerative diseases. Its success depends on clinical results. This overall economic activity graph doesn't directly affect its operations, but the overall growth in wealth provides long-term funding for healthcare innovation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Annexon Inc.
Annexon is a clinical-stage biotechnology company developing drugs to treat autoimmune and neurodegenerative diseases by targeting the complement system. This projected revenue graph reflects expectations for its scientific approach. Its dynamics are driven by analyst confidence in the success of its clinical trials.
%20sales%20of%20the%20company%20Annexon%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Annexon-Inc.&v=1772604425207 "Schedule of future (projected) sales of the company Annexon Inc.")
Future (projected) sales of companies in the market segment - Neuro
Annexon is a clinical-stage biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the C1q component of the classical complement cascade. This chart shows projected revenues for the entire neuroscience sector, reflecting the search for new approaches to treating these complex diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772604425349 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Annexon is a biotechnology company specializing in the treatment of neurodegenerative and autoimmune diseases. Its success depends on scientific breakthroughs and clinical trial results. A positive economic environment is stimulating capital inflows into the biotechnology sector, allowing the company to fund its research activities.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772604425402 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Annexon Inc.
Annexon is a clinical-stage biopharmaceutical company developing drugs for the treatment of autoimmune and neurodegenerative diseases. This chart shows the cost of its innovative approach. It reflects the R&D investment required to validate a new scientific hypothesis and bring candidates to market.
Market segment marginality - Neuro
Annexon is a biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the complement system. This chart reflects its financial performance. For a clinical-stage company, the comparison with the sector shows how effectively it manages its significant R&D costs.
Market marginality as a whole
Annexon is a biotech company specializing in the treatment of autoimmune and neurodegenerative diseases. Its success depends solely on the results of clinical trials, not on the economic situation, as reflected in this chart. The need for effective treatments for these diseases is a constant driver.
Employees in the company, segment and market as a whole
Number of employees in the company Annexon Inc.
Annexon is a biotech company developing drugs that target components of the immune system to treat neurodegenerative diseases. This chart shows its growing team of scientists. The increase in staff reflects the progress of its clinical programs and the complexity of drug development for diseases like Huntington's disease.
Share of the company's employees Annexon Inc. within the market segment - Neuro
Annexon is a biotech company developing treatments for neurodegenerative and autoimmune diseases. Its approach is based on rigorous scientific research conducted by a small but elite team. This underscores its research-intensive nature: value is created in the laboratory, not through the scale of its workforce.
Number of employees in the market segment - Neuro
Annexon is a biotechnology company developing drugs to treat autoimmune and neurodegenerative diseases by targeting the complement component C1q. This graph highlights its cutting-edge scientific approach. The growth of its research staff reflects progress in clinical trials of this innovative platform, which has potential applications across a wide range of diseases.
Number of employees in the market as a whole
Annexon is a biopharmaceutical company developing drugs for the treatment of autoimmune and neurodegenerative diseases. Its staff consists of highly qualified scientists. This employment chart highlights that in the biotech sector, hiring dynamics depend not on the state of the economy, but on progress in clinical trials and strategic investments in R&D.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Annexon Inc. (ANNX)
Annexon is a biopharmaceutical company developing drugs targeting the classical complement cascade, which plays a role in autoimmune and neurodegenerative diseases. This chart demonstrates the company's enormous cost per employee. This is typical for biotech, where market valuation is based on the potential of the scientific platform rather than current revenue.
%20of%20the%20company%20Annexon%20Inc.%20(ANNX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Annexon-Inc.-ANNX&v=1772604425698 "Chart of market capitalization per employee (in thousands of dollars) of the company Annexon Inc. (ANNX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Annexon is a biopharmaceutical company specializing in the treatment of autoimmune and neurodegenerative diseases through complement inhibition. In this complex area of medicine, this metric reflects the market's confidence in their scientific approach. A high score indicates that investors see significant potential in their platform for developing a new class of drugs.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772604425709 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Annexon is a biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases. This metric reflects a business at the forefront of immunology. Its market capitalization is based on the potential of its scientific platform. The team's efforts could lead to the creation of a new class of drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772604425730 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Annexon Inc. (ANNX)
Annexon is a clinical-stage biotech focused on treating autoimmune and neurodegenerative diseases by blocking C1q. They are not profitable. This chart shows the loss per employee. This is the cost of burning through R&D budgets in pursuit of a breakthrough.
%20Chart%20Annexon%20Inc.%20(ANNX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Annexon-Inc.-ANNX&v=1772604425755 "Company Profit Per Employee (in thousands of dollars) Chart Annexon Inc. (ANNX)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Annexon is a biotech company specializing in the treatment of autoimmune and neurodegenerative diseases. The company has no profit, only R&D expenses. This metric reflects capital burn per employee, which investors compare to industry standards to assess discipline in R&D spending.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772604425760 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Annexon is a biotech company developing drugs to treat autoimmune and neurodegenerative diseases by inhibiting the C1q protein. This is a deep R&D company. This graph shows the negative value—the high cost of maintaining a team of elite scientists working on this innovative, but risky, treatment approach.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772604425793 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Annexon Inc. (ANNX)
Annexon is a biopharmaceutical company developing drugs to treat autoimmune and neurodegenerative diseases. This graph is typical for a clinical-stage company. The lack of revenue per employee means that all of the company's resources and value are focused on the potential of its innovative developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Annexon-Inc.-ANNX&v=1772604425823 "Sales chart per company employee Annexon Inc. (ANNX)")
Sales per employee in the market segment - Neuro
Annexon (ANNX) is a biotech company specializing in the treatment of autoimmune and neurodegenerative diseases by inhibiting the complement system in the brain and body. This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their R&D platform in this complex field.
Sales per employee for the market as a whole
Annexon (ANNX) is a biopharmaceutical company developing therapies for autoimmune and neurodegenerative diseases by blocking the classical complement pathway. This is an R&D business. The company has no commercial revenue from drug sales. This figure is currently close to zero.
Short shares by company, segment and market as a whole
Shares shorted by company Annexon Inc. (ANNX)
Annexon is a biotech company specializing in the treatment of neurological and autoimmune diseases. This chart shows bearish bets. Bears are betting on a high risk of clinical trial failure. Neurology is one of the most complex fields, where failures are very common.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Annexon-Inc.-ANNX&v=1772604425886 "Short Shares Chart for the Company Annexon Inc. (ANNX)")
Shares shorted by market segment - Neuro
Annexon is a biotech company developing drugs targeting the complement system (part of the immune system) to treat neurological and autoimmune diseases. This chart shows bearish sentiment. "Shorts" here are betting that their scientific approach will be proven wrong.
Shares shorted by the overall market
Annexon (ANNX) is another biotech company developing therapies for neurodegenerative diseases. Like its peers, the company lacks stable revenue. This market pessimism chart shows "risk appetite." When it declines, ANNX shares, which depend on future research success, experience intense selling pressure.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Annexon Inc. (ANNX)
Annexon is a biotech company focused on treating neurodegenerative diseases (Huntington's disease). It's an extremely risky R&D bet. This chart measures the extremes of speculative sentiment. It shows when the stock is "overbought" on positive data or "oversold" on negative news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Annexon-Inc.-ANNX&v=1772604425948 "RSI 14 indicator chart for the company's stock Annexon Inc. (ANNX)")
RSI 14 Market Segment - Neuro
Annexon is a biotech company specializing in the treatment of neurodegenerative and autoimmune diseases by inhibiting C1q, a protein that triggers synapse depletion. This chart measures the collective excitement in the neuroscience biotech sector. It helps determine whether the entire segment is overheated by anticipation of a treatment breakthrough.
RSI 14 for the overall market
For Annexon, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ANNX (Annexon Inc.)
Annexon is a biotech company developing drugs targeting C1q, a protein that activates the complement system. Their goal is to treat neurodegenerative and autoimmune diseases. This chart shows the analysts' average 12-month forecast, representing their collective bet on the success of this scientific platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ANNX-Annexon-Inc.&v=1772604426016 "A chart showing analyst consensus forecasts for the expected stock price. ANNX (Annexon Inc.)")
The difference between the consensus estimate and the actual stock price ANNX (Annexon Inc.)
Annexon is a biotech company whose scientific approach is based on blocking the C1q protein to treat severe autoimmune and neurodegenerative diseases. This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the price and forecast, reflecting their belief in this unique scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ANNX-Annexon-Inc.&v=1772604426048 "A chart showing the difference between the consensus forecast and the actual stock price. ANNX (Annexon Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Annexon is a biotech company developing therapies for autoimmune and neurodegenerative diseases by blocking C1q, a protein that mistakenly triggers an immune system attack. This chart shows analysts' overall expectations for the neuroscience sector, reflecting their confidence in the success of this R&D approach.
Analysts' consensus forecast for the overall market share price
Annexon is a biotech company specializing in developing drugs to treat neurodegenerative and autoimmune diseases by blocking the brain's complement system. This chart shows overall risk appetite. For Annexon, which operates in the complex field of neuroscience, overall market optimism is critical to funding long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Annexon Inc.
Annexon is a biotech company focused on treating complement-mediated autoimmune and neurodegenerative diseases. They are trying to calm the overactive immune system. This graph is a pure reflection of their science. Its dynamics depend entirely on their progress in clinical trials in this complex area of immunology.
AKIMA Market Segment Index - Neuro
Annexon (ANNX) is a clinical-stage biotech and a pioneer in immuno-neurology (like Alector). The company develops drugs (C1q inhibitors) that block the immune system's attack on the brain (for the treatment of rare neurological diseases). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this breakthrough R&D platform (ANNX) differentiate it from the average pharma company?
The AKIM Index for the overall market
Annexon is a biopharmaceutical company developing treatments for autoimmune, ophthalmological, and neurodegenerative diseases (complement C1q). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this clinical story with a broad pipeline compares to overall economic trends.
